---
layout: post
title: "Receipt of Notice That a Patent Infringement Complaint Was Filed Against a Biosimilar or Interchangeable Biosimilar Applicant"
date: 2026-02-05 18:58:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-02799
original_published: 2022-02-10 00:00:00 +0000
significance: 8.00
---

# Receipt of Notice That a Patent Infringement Complaint Was Filed Against a Biosimilar or Interchangeable Biosimilar Applicant

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** February 10, 2022 00:00 UTC
**Document Number:** 2022-02799

## Summary

The Food and Drug Administration (FDA) is publishing notice that an applicant for a biologics license application (BLA) for a biosimilar or interchangeable biosimilar product submitted under the Public Health Service Act (PHS Act) (a "subsection (k) applicant") notified FDA that an action for patent infringement was filed in connection with the applicant's BLA. Under the PHS Act, within 30 days after the subsection (k) applicant is served with a complaint in an action for patent infringement described under the PHS Act, the subsection (k) applicant shall provide the Secretary of HHS with notice and copy of such complaint. FDA is required to publish notice of the complaint in the Federal Register.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/02/10/2022-02799/receipt-of-notice-that-a-patent-infringement-complaint-was-filed-against-a-biosimilar-or)
- API: https://www.federalregister.gov/api/v1/documents/2022-02799

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
